NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT03611738 2026-02-09
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT02393625 2026-02-03
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Novartis
Phase 1 Active not recruiting
NCT02584933 2026-02-03
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting